# Genprex

Source: https://onco.cc/companies/genprex/  
OnCo record `genprex` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Genprex is a United States-based biotechnology company running 2 late-stage cancer trials of quaratusugene ozeplasmid in non-small-cell lung cancer and small-cell lung cancer.

## Summary

Genprex, based in Austin, the United States, is a biotechnology company. Genprex is a clinical-stage gene therapy company developing treatments for cancer and diabetes by reintroducing tumour suppressor genes. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing quaratusugene ozeplasmid in non-small-cell lung cancer and small-cell lung cancer. The largest, NCT04486833 (Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib), plans to enrol 158 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Genprex, Inc.
- Tags: ctgov-sponsor
- HQ: Austin
- Type: biotech
- Website: https://www.genprex.com

## Sources

- Official website: https://www.genprex.com
- ClinicalTrials.gov: trials led by Genprex: https://clinicaltrials.gov/search?lead=Genprex%2C%20Inc.

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- trials: [Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients](https://onco.cc/trials/nct05703971/), [Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib](https://onco.cc/trials/nct04486833/)

---
JSON: https://onco.cc/api/v1/entities/genprex.json